The efficacy of new treatment methods in HCV patients: a single center study

Abstract

ABSTRACT Aim: Achieving sustained virologic response (SVR) is critical in patients with chronic hepatitis C virus (HCV) infection. Over the last few years, many developments have been made in HCV infection treatment with the evaluation of direct-actinga antivirals (DAAs). Treatment with DAAs resulted in high rates of SVR among patients with chronic HCV infection. The aim of our study aim to compare the treatment efficacy between different DAA regimens in patients with HCV. Methods: In our study 290 patients were evaluated retrospectively with regard to the effects related to the use of DAAs and its effects on HCV-RNA. The primary end point was a SVR at 12 weeks after the end of the DAA therapy. Results: In our study included 290 patients who were treated with DAA. The rate of SVR was 99% (98%; 95 confidence interval [CI], 96 to 100) with 12 weeks of ledipasvir plus sofosbuvir (LDV+SOF), 96% (97.9%; 95% CI, 94 to 99) with 12 weeks of sofosbuvir plus ribavirin (SOF+RBV), and 90% (98.9%; 95% CI, 95 to 99) with 12 weeks of ombitasvir/paritaprevir/ritonavir plus dasabuvir (PrOD). In comparing LDV+SOF, SOF+RBV and PrOD, the chance of having SVR between these three DAA regimens was not significantly different. Conclusion: DAA treatment regimens should be preferred in the first line drug for the treatment of chronic HCV infection because of the their significant clinical benefits.